Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

CompletedOBSERVATIONAL
Enrollment

823

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Overactive BladderUrinary Incontinence
Interventions
DRUG

fesoterodine

4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment

Trial Locations (65)

82109

Pfizer Investigational Site, Bratislava

82606

Pfizer Investigational Site, Bratislava

85104

Pfizer Investigational Site, Bratislava

85107

Pfizer Investigational Site, Bratislava

90122

Pfizer Investigational Site, Malacky

90501

Pfizer Investigational Site, Senica

90901

Pfizer Investigational Site, Skalica

Unknown

Pfizer Investigational Site, ?a?a

Pfizer Investigational Site, Aa

Pfizer Investigational Site, Adca

Pfizer Investigational Site, B.Bystrica

Pfizer Investigational Site, Bardejov

Pfizer Investigational Site, Bratislava

Pfizer Investigational Site, Dolný Kubín

Pfizer Investigational Site, Dunajská Streda

Pfizer Investigational Site, Hlohovec

Pfizer Investigational Site, Humenné

Pfizer Investigational Site, Ilina

Pfizer Investigational Site, Koice-aca

Pfizer Investigational Site, Koice

Pfizer Investigational Site, Komárno

Pfizer Investigational Site, Košice

Pfizer Investigational Site, Kraovsky Chlmec

Pfizer Investigational Site, Liptovský Hrádok

Pfizer Investigational Site, Liptovský Mikuláš

Pfizer Investigational Site, Luenec

Pfizer Investigational Site, Martin

Pfizer Investigational Site, Michalovce

Pfizer Investigational Site, Myjava

Pfizer Investigational Site, Námestovo

Pfizer Investigational Site, Nitra

Pfizer Investigational Site, Nové Zámky

Pfizer Investigational Site, Poprad

Pfizer Investigational Site, Povaska Bystrica

Pfizer Investigational Site, Preov

Pfizer Investigational Site, Prievidza

Pfizer Investigational Site, Púchov

Pfizer Investigational Site, Revúca

Pfizer Investigational Site, Rimavská Sobota

Pfizer Investigational Site, Ruomberok

Pfizer Investigational Site, Ružomberok

Pfizer Investigational Site, Sobrance

Pfizer Investigational Site, SpisskaNova Ves

Pfizer Investigational Site, Stropkov

Pfizer Investigational Site, Svidník

Pfizer Investigational Site, Topoany

Pfizer Investigational Site, Trebišov

Pfizer Investigational Site, Trenin

Pfizer Investigational Site, Trnava

Pfizer Investigational Site, Turianske Teplice

Pfizer Investigational Site, Urany

Pfizer Investigational Site, Vranov n/Topou

Pfizer Investigational Site, Vráble

Pfizer Investigational Site, Zvolen

974 01

Pfizer Investigational Site, Banská Bystrica

833 05

Pfizer Investigational Site, Bratislava

851 01

Pfizer Investigational Site, Bratislava

851 05

Pfizer Investigational Site, Bratislava

041 90

Pfizer Investigational Site, Košice

901 01

Pfizer Investigational Site, Malacky

949 01

Pfizer Investigational Site, Nitra

951 01

Pfizer Investigational Site, Nitra

921 01

Pfizer Investigational Site, Piešťany

017 01

Pfizer Investigational Site, Považská Bystrica

911 01

Pfizer Investigational Site, Trenčín

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00691093 - Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy | Biotech Hunter | Biotech Hunter